莫西沙星方案治疗复发性药物敏感肺结核:开放标签随机对照试验
该开放标签随机对照试验纳入196例复发性药物敏感肺结核患者,比较含莫西沙星方案与标准方案。莫西沙星组8周末痰培养转阴率与对照组无显著差异,治疗成功比例亦无显著改善,但培养转阴中位时间更短,且3/4级不良事件和严重不良事件发生率显著更高。
要点
- 莫西沙星替代乙胺丁醇未显著提高8周末痰培养转阴率或治疗成功率。
- 莫西沙星组培养转阴中位时间显著缩短,但不良事件发生率显著更高。
- 复发性药物敏感肺结核沿用标准方案可能更安全,莫西沙星方案需权衡风险。
核心结论
- 以莫西沙星替代乙胺丁醇未显著改善8周末培养转阴率或治疗成功,且不良事件发生率更高。
研究设计与样本
- 开放标签随机对照试验,纳入196例复发性药物敏感肺结核患者,比较含莫西沙星方案与标准方案。
临床怎么用
- 复发性药物敏感肺结核采用含莫西沙星方案替代乙胺丁醇未显示治疗获益,且不良事件更多,临床决策需谨慎权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The substitution of moxifloxacin for ethambutol produced promising results for improved tuberculosis treatment outcomes. METHODS: We conducted an open-label, randomized trial to test whether a moxifloxacin-containing treatment regimen was superior to the standard regimen for the treatment of recurrent tuberculosis. The primary and secondary outcomes were the sputum culture conversion rate at the end of 8 weeks and the proportion of participants with a favorable outcome, respectively. RESULTS: We enrolled 196 participants; 69.9% were male and 70.4% were co-infected with human immunodeficiency virus (HIV). There was no significant difference between the study groups in the proportion of patients achieving culture conversion at the end of 8 weeks (83.0% [moxifloxacin] vs 78.5% [control]; P = .463); however, the median time to culture conversion was significantly shorter (6.0 weeks, interquartile range [IQR] 4.0-8.3) in the moxifloxacin group than the control group (7.9 weeks, IQR 4.0- 11.4; P = .018). A favorable end-of-treatment outcome was reported in 86 participants (87.8%) in the moxifloxacin group and 93 participants (94.9%) in the control group, for an adjusted absolute risk difference of -5.5 (95% confidence interval -13.8 to 2.8; P = .193) percentage points. There were significantly higher proportions of participants with Grade 3 or 4 adverse events (43.9% [43/98] vs 25.5% [25/98]; P = .01) and serious adverse events (27.6% [27/98] vs 12.2% [12/98]; P = .012) in the moxifloxacin group. CONCLUSIONS: The replacement of ethambutol with moxifloxacin did not significantly improve either culture conversion rates at the end of 8 weeks or treatment success, and was associated with a higher incidence of adverse events. CLINICAL TRIALS REGISTRATION: NCT02114684.
引用
- Perumal R, Padayatchi N, Yende-Zuma N, et al. A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomized, Controlled Trial. Clin Infect Dis. 2020. PMID: 30809633. doi:10.1093/cid/ciz152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。